Review on endobronchial therapies-current status and future
- PMID: 39118957
- PMCID: PMC11304415
- DOI: 10.21037/atm-23-1430
Review on endobronchial therapies-current status and future
Abstract
There is a growing demand for lung parenchymal-sparing localized therapies due to the rising incidence of multifocal lung cancers and the growing number of patients who cannot undergo surgery. Lung cancer screening has led to the discovery of more pre-malignant or early-stage lung cancers, and the focus has shifted from treatment to prevention. Transbronchial therapy is an important tool in the local treatment of lung cancers, with microwave ablation showing promise based on early and mid-term results. To improve the precision and efficiency of transbronchial ablation, adjuncts such as mobile C-arm platforms, software to correct for computed tomography (CT)-to-body divergence, metal-containing nanoparticles, and robotic bronchoscopy are useful. Other forms of energy such as steam vapor therapy, pulsed electric field, and photodynamic therapy are being intensively investigated. In addition, the future of transbronchial therapies may involve the intratumoral injection of novel agents such as immunomodulating agents, gene therapies, and chimeric antigen receptor T cells. Extensive pre-clinical and some clinical research has shown the synergistic abscopal effect of combination of these agents with ablation. This article aims to provide the latest updates on these technologies and explore their most likely future applications.
Keywords: Transbronchial ablation; microwave ablation; photo dynamic therapy; pulsed electric field; robotic bronchoscopy.
2024 Annals of Translational Medicine. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-1430/coif). The series “Lung Cancer Management—The Next Decade” was commissioned by the editorial office without any funding or sponsorship. C.S.H.N. served as the unpaid Guest Editor of the series and serves as the Editor-in-Chief of Annals of Translational Medicine from January 2022 to December 2023. He is also a consultant for Johnson and Johnson, Medtronic USA and Siemens Healthineer. R.W.H.L. is a consultant for Medtronic USA and Siemens Healthineer. The authors have no other conflicts of interest to declare.
Figures
References
-
- Chan JWY, Lau R, Chang A, et al. 96P Transbronchial microwave ablation: Important role in the battle of lung preservation for multifocal lung primaries or metastases. Ann Oncol 2022;33:S76-7.
Publication types
LinkOut - more resources
Full Text Sources